Alpa Laboratories Ltd
Alpa Laboratories Ltd (ALPA) last reported results for the quarter ended Jun 2026, with sales of ₹23.93 crore and net profit of ₹0.98 crore. The stock last traded at ₹58.6, a market capitalisation of ₹123 crore, on a P/E of 30.3. Over the past 52 weeks the stock has ranged between ₹46 and ₹99.8. Figures are as of 6 Oct 2026 and are not real time.
Alpa Laboratories Ltd share price and key metrics
- Current price
- ₹58.6
- Market cap
- ₹123 cr
- Stock P/E
- 30.3
- Book value
- ₹88.5
- ROE
- 8.38%
- ROCE
- 9.40%
- Dividend yield
- 0.00%
- 52w high / low
- 99.8/46.0
Metrics as of 6 Oct 2026. Not real time.
Track Alpa Laboratories Ltd
Cruxal reads every Alpa Laboratories Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Alpa Laboratories Ltd growth and returns
- 10 Years
- 7%
- 5 Years
- 2%
- 3 Years
- 4%
- TTM
- 0%
- 10 Years
- 8%
- 5 Years
- 24%
- 3 Years
- 6%
- TTM
- -85%
- 10 Years
- 6%
- 5 Years
- 0%
- 3 Years
- -8%
- 1 Year
- -34%
- 10 Years
- 7%
- 5 Years
- 10%
- 3 Years
- 11%
- Last Year
- 8%
Alpa Laboratories Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹23.93 cr, up 25.2% from ₹19.11 cr a year earlier. Net profit was ₹0.98 cr, down 91.7% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 24.94 | 26.15 | 39.92 | 19.11 | 26.26 | 29.05 | 31.4 | 23.93 |
| Expenses | 21.62 | 25.41 | 39.72 | 18.68 | 28.51 | 27.54 | 27.8 | 27.89 |
| Operating profit | 3.32 | 0.74 | 0.2 | 0.43 | -2.25 | 1.51 | 3.6 | -3.96 |
| OPM % | 13.31% | 2.83% | 0.50% | 2.25% | -8.57% | 5.20% | 11.46% | -16.55% |
| Other income | 6.91 | 8.8 | 2.48 | 11.94 | 3.06 | 0.91 | -0.16 | 5.77 |
| Interest | 0.05 | 0.09 | 0.02 | 0.05 | 0.03 | 0.03 | 0.15 | 0.11 |
| Depreciation | 0.53 | 0.55 | 0.58 | 0.55 | 0.67 | 0.65 | 0.22 | 0.72 |
| Profit before tax | 9.65 | 8.9 | 2.08 | 11.77 | 0.11 | 1.74 | 3.07 | 0.98 |
| Tax % | 20.31% | 0.00% | 201.92% | 0.00% | 0.00% | 9.20% | 55.05% | 0.00% |
| Net profit | 7.69 | 8.9 | -2.12 | 11.77 | 0.11 | 1.59 | 1.38 | 0.98 |
| EPS (₹) | 3.65 | 4.23 | -1.01 | 5.59 | 0.05 | 0.76 | 0.66 | 0.47 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Alpa Laboratories Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 63 | 62 | 77 | 85 | 97 | 112 | 93 | 109 | 110 | 106 | 111 |
| Operating profit | 7 | 4 | 1 | 6 | 8 | 11 | 8 | 9 | 5 | 3 | -1 |
| OPM % | 11% | 7% | 1.5% | 7% | 8% | 10% | 9% | 8% | 4.4% | 3.1% | -1.0% |
| Net profit | 3 | 3 | 1 | 2 | 7 | 14 | 13 | 17 | 20 | 15 | 4 |
| EPS (₹) | 1.20 | 1.34 | 0.48 | 0.88 | 3.45 | 6.70 | 5.98 | 7.98 | 9.27 | 7.13 | 1.94 |
TTM is the trailing twelve months to the most recent quarter.
Alpa Laboratories Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 |
| Reserves | 74 | 77 | 77 | 79 | 87 | 101 | 114 | 131 | 151 | 165 |
| Borrowings | 11 | 6 | 2 | 0 | 0 | 6 | 2 | 5 | 0 | 3 |
| Other liabilities | 20 | 18 | 21 | 21 | 33 | 28 | 30 | 25 | 51 | 53 |
| Total liabilities | 126 | 122 | 121 | 121 | 140 | 155 | 167 | 182 | 223 | 242 |
| Fixed assets | 15 | 10 | 8 | 6 | 7 | 9 | 7 | 11 | 21 | 20 |
| CWIP | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 |
| Investments | 13 | 31 | 49 | 57 | 51 | 75 | 78 | 98 | 118 | 142 |
| Other assets | 97 | 81 | 65 | 58 | 81 | 71 | 82 | 73 | 84 | 80 |
| Total assets | 126 | 122 | 121 | 121 | 140 | 155 | 167 | 182 | 223 | 242 |
As reported by the company. Total assets equal total liabilities by construction.
Alpa Laboratories Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 17 | -13 | -1 | 18 | -2 | 10 | 9 | 4 | 18 | 9 |
| Cash from investing | -2 | -11 | -15 | -11 | 6 | -16 | 2 | -13 | -12 | -11 |
| Cash from financing | -15 | 9 | -5 | -1 | 0 | 5 | -4 | 3 | -5 | 2 |
| Net cash flow | 0 | -15 | -20 | 5 | 4 | -0 | 7 | -7 | 1 | 1 |
| Free cash flow | 16 | -15 | -2 | 15 | -5 | 8 | 8 | -3 | 7 | 6 |
| CFO / operating profit | 283% | -263% | 102% | 324% | 15% | 123% | 155% | 85% | 466% | 369% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Alpa Laboratories Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 8% | 6% | 3% | 5% | 7% | 9% | 12% | 15% | 16% | 9% |
| Debtor days | 168 | 153 | 142 | 105 | 133 | 124 | 184 | 138 | 155 | 141 |
| Inventory days | 131 | 138 | 105 | 90 | 102 | 81 | 84 | 73 | 92 | 73 |
| Days payable | 140 | 134 | 99 | 98 | 152 | 78 | 100 | 63 | 97 | 98 |
| Cash conversion cycle | 159 | 157 | 149 | 97 | 83 | 127 | 168 | 149 | 150 | 116 |
| Working capital days | 174 | 208 | 194 | 125 | 140 | 118 | 152 | 135 | 110 | 71 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Alpa Laboratories Ltd shareholding pattern
Promoters held 57.19% at Jun 2026, broadly unchanged since Jun 2025. FIIs 0.35% and DIIs 0.07%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 57.29% | 57.29% | 57.29% | 57.29% | 57.29% | 57.29% | 57.19% | 57.19% |
| FIIs | 0.74% | 0.35% | 0.40% | 0.36% | 0.35% | 0.36% | 0.38% | 0.35% |
| DIIs | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.07% |
| Public | 41.97% | 42.34% | 42.30% | 42.34% | 42.36% | 42.35% | 42.43% | 42.38% |
| No. of shareholders | 18,885 | 19,206 | 18,872 | 18,851 | 18,542 | 18,236 | 17,900 | 17,643 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Alpa Laboratories Ltd corporate filings
- Alpa Laboratories holds AGM; no new financial disclosures or strategic updates providedAGM/EGMlow impact
Cruxal's analysis: Alpa Laboratories Limited conducted its 38th Annual General Meeting on 30 September 2026…
Read the full analysis - Intimation of closure of trading window.Insider Trading / SASTlow impact
- Alpa Laboratories Ltd. appoints Ms. Diksha Jaswani as Company Secretary and Compliance OfficerCompany Updatelow impact
Cruxal's analysis: Alpa Laboratories Ltd. has announced the appointment of Ms. Diksha Jaswani as the Company…
Read the full analysis - Alpa Laboratories Ltd releases Annual Report for FY2026Otherslow impact
Cruxal's analysis: Alpa Laboratories has filed its Annual Report for the financial year ended March 31…
Read the full analysis - Alpa Laboratories Ltd. Announces Book Closure Dates for 38th Annual General MeetingCorp. Actionlow impact
Cruxal's analysis: Alpa Laboratories Ltd. has formally notified the stock exchanges regarding the scheduling…
Read the full analysis - Alpa Laboratories Ltd. appoints new Independent Director and reconstitutes board committeesCompany Updatelow impact
Cruxal's analysis: Alpa Laboratories Ltd. has announced the appointment of Mrs. Radhika Biyani as an…
Read the full analysis - Alpa Laboratories reports Q1 FY27 results with significant decline in profitability and operational performanceResulthigh impact
Cruxal's analysis: Alpa Laboratories Ltd. reported a sharp decline in financial performance for the quarter…
Read the full analysis - Alpa Laboratories Ltd. issues clarification on Board Meeting dateCompany Updatelow impact
Cruxal's analysis: Alpa Laboratories Ltd. has issued a formal clarification regarding a typographical error…
Read the full analysis - Alpa Laboratories Board to Meet on August 13, 2026, to Approve Q1 FY27 Financial Results and 38th AGM NoticeBoard Meetinglow impact
Cruxal's analysis: Alpa Laboratories Ltd. has announced that its Board of Directors will convene on…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.